+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics & Biosimilars CXO Services Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Biologics & Biosimilars CXO Services Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Biologics & Biosimilars CXO Services Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6079859
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The biologics and biosimilars sector stands at a crucial inflection point, driven by breakthroughs in molecular engineering and an evolving regulatory environment. As novel therapies such as cell and gene therapies advance from laboratory innovation to clinical reality, stakeholders must navigate a complex fabric of technological, economic, and policy dynamics. This executive summary delivers a concise yet comprehensive overview of the forces shaping the landscape, equipping decision-makers with the insights required to capitalize on emerging opportunities and mitigate risks. By examining transformative shifts, the ramifications of new trade policies, granular segmentation analysis, and regional and competitive dynamics, this report provides a strategic blueprint for executives seeking to maintain leadership in this high-growth arena.

Transformative Shifts Reshaping the Industry

Over the past five years, the industry has undergone several pivotal transformations. Advances in cell therapy and gene therapy have moved personalized medicine from concept to clinic, catalyzing a surge in recombinant proteins and monoclonal antibody pipelines. Simultaneously, digital manufacturing technologies have enabled continuous manufacturing platforms that enhance process efficiency and product consistency. Regulatory bodies have adapted, introducing expedited pathways that facilitate accelerated approval for breakthrough biologics and biosimilars, fostering a more competitive market environment.

Moreover, the competitive dynamic has shifted as emerging players leverage synthetic biology and microbial expression systems to challenge established incumbents. Collaborative models between contract manufacturing organizations and research institutions have proliferated, allowing for greater flexibility and scalability. These converging trends have established a new paradigm in which agility, technological integration, and strategic alliances determine market leadership.

Cumulative Impact of United States Tariffs in 2025

Effective January 2025, sweeping tariff adjustments on imported biologics components have altered supply chain economics. Tariffs on key raw materials sourced from Europe and Asia-Pacific have introduced additional cost pressures, prompting manufacturers to reengineer sourcing strategies and localize critical process steps. The cumulative effect of these tariffs has increased production expenses for recombinant proteins and monoclonal antibodies, particularly those dependent on microbial - bacterial expression systems and animal-derived substrates.

In response, several contract manufacturing organizations have accelerated investments in domestic upstream processing facilities to minimize exposure. Meanwhile, end-users such as hospitals and clinics are negotiating framework agreements to secure more predictable pricing. While nearshoring has risen in prominence, universities and research organizations are exploring synthetic or human cell-based alternatives that bypass tariff-impacted raw materials. These adaptive measures underscore the industry’s resilience but also highlight the need for strategic risk management as global trade dynamics continue to evolve.

Key Segmentation Insights Across Multiple Dimensions

Insight into market segmentation reveals differentiated growth trajectories across product types, from pioneering cell therapy platforms and gene therapy constructs to established hormone formulations, monoclonal antibodies, recombinant proteins, and various vaccines. Within therapeutic applications, autoimmune diseases-exemplified by targeted therapies for Crohn’s disease and rheumatoid arthritis-remain a high-value segment, while oncology treatments focused on breast, colorectal, and lung cancers continue to command significant R&D resources and commercial investment.

End-user demand spans clinics seeking outpatient infusion services, contract manufacturing organizations expanding capacity, hospitals requiring scalable biosimilar portfolios, and research organizations advancing early-stage discovery. Source diversity ranges from animal-derived and human cell systems to microbial expression routes-both bacterial and viral-and fully synthetic approaches, each carrying unique cost and regulatory profiles. Manufacturing processes are evolving toward continuous manufacturing with integrated upstream and downstream processing, meeting stringent quality standards and reducing batch variability.

Route of administration influences product positioning, with intravenous formulations dominating hospital settings and subcutaneous formats gaining traction for self-administration. Molecular types bifurcate into large molecules with complex glycosylation patterns and small molecules with streamlined production demands. Development stages bifurcate into clinical and preclinical, underscoring a robust pipeline. Therapeutic areas include endocrinology and immunology, the latter encompassing treatments for allergies and immunodeficiency disorders, driving differentiated market strategies. Sales channels encompass direct sales agreements, distributor networks, and emerging online platforms. Across patent status, both off-patent and patented biologics present distinct commercialization pathways, while drug classification alternates between over-the-counter and prescription-based models. Treatment duration spans acute interventions and chronic management therapies, each demanding tailored support programs and patient adherence strategies.

Collectively, these segmentation layers illuminate the nuanced drivers behind investment decisions, product development roadmaps, and market entry tactics, enabling stakeholders to prioritize high-impact segments and optimize resource deployment.

Key Regional Insights Driving Market Dynamics

Regional analysis underscores distinctive dynamics within the Americas, where established markets benefit from advanced reimbursement frameworks and a mature biosimilars ecosystem. North America’s robust clinical trial infrastructure and high patient uptake rates drive early adoption of innovative therapies, while Latin American markets present both challenges in regulatory alignment and opportunities for capacity expansion through cross-border partnerships.

In Europe, Middle East & Africa, the emphasis on cost containment and centralized regulatory coordination has accelerated biosimilar approvals, delivering price competition and expanded access. The European Union’s well-defined interchangeability guidelines foster confidence among health authorities and payers, while Middle Eastern and African markets are showing growing interest in public-private collaborations to build local manufacturing capacity.

Asia-Pacific exhibits diverse market maturity levels, from advanced economies with rigorous quality standards to emerging markets where government incentives are revitalizing domestic biologics production. National strategies in countries such as South Korea and China emphasize self-sufficiency through technology transfer and joint ventures, whereas India leverages its generics expertise to become a key global supplier of off-patent biologics. These regional nuances call for tailored market entry strategies and adaptive pricing models to capture full growth potential.

Key Company Insights and Competitive Landscape

The competitive landscape features a blend of innovation powerhouses and specialized biosimilar developers. Alexion Pharmaceuticals, now an AstraZeneca subsidiary, leads in rare disease and complement biology, while Amgen excels in oncology and immunology with a diversified monoclonal antibody portfolio. Biocon Limited brings microbial expression expertise and cost-effective fermentation platforms, whereas Boehringer Ingelheim focuses on autoimmune and respiratory biologics through strategic acquisitions.

Celltrion and Samsung Bioepis have emerged as front-runners in the biosimilars space, leveraging scale to challenge patented incumbents. Dr. Reddy’s Laboratories and Lupin Limited extend their generics heritage into recombinant proteins, targeting both emerging and developed markets. Eli Lilly and Company maintains its leadership in diabetes and oncology, supported by advanced continuous manufacturing capabilities. Fresenius Kabi and Sandoz International GmbH reinforce supply chain resilience for infusion therapies and supportive care biologics.

Genentech, a Roche subsidiary, continues to push the envelope in personalized oncology, while Merck & Co. and Pfizer maintain broad pipelines spanning vaccines, hormones, and monoclonal antibodies. Mylan’s integration into Viatris enhances its global distribution network for off-patent biologics, and Sanofi S.A. leverages its immunology expertise across autoimmune and allergy indications. STADA Arzneimittel AG and Teva Pharmaceutical Industries Ltd. round out the field with strategic biosimilar launches and strong presence in chronic therapy segments. This multifaceted roster underscores the imperative for strategic partnerships, technology alliances, and lifecycle management programs to sustain competitive advantage.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integration of advanced analytics and digital twins to optimize continuous manufacturing workflows and predictive maintenance. Expanding strategic alliances with contract manufacturing organizations will enable flexibility to navigate tariff-induced supply chain pressures. Organizations must also deepen engagement with regulatory authorities to anticipate changes in interchangeability guidelines and expedite product approvals.

In addition, tailoring commercialization strategies to high-value segments-such as oncology biosimilars and immunology treatments-will maximize ROI. Investment in patient support programs for chronic therapies will differentiate brands and improve adherence. Finally, leveraging online sales channels alongside traditional distribution networks can accelerate market penetration and foster direct engagement with healthcare providers and patients.

Conclusion: Navigating the Future of Biologics and Biosimilars

The biologics and biosimilars market stands poised for sustained expansion, driven by technological innovation, strategic collaborations, and evolving regulatory frameworks. Navigating this complexity requires a holistic approach that integrates supply chain resilience, targeted segmentation strategies, and agile commercialization models. By aligning investment priorities with emerging high-impact segments and leveraging competitive intelligence, organizations can secure leadership positions.

The ability to adapt swiftly to tariff changes, capitalize on regional nuances, and harness the strengths of both innovative and biosimilar players will define success in the coming years. Establishing robust alliances across the value chain and embedding digital transformation at the core of operations will ensure scalability and sustained market relevance.

Market Segmentation & Coverage

This research report categorizes the Biologics & Biosimilars CXO Services Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Cell Therapy
  • Gene Therapy
  • Hormones
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Autoimmune Diseases
    • Crohn's Disease
    • Rheumatoid Arthritis
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurological Disorders
  • Oncology
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
  • Clinics
  • Contract Manufacturing Organizations
  • Hospitals
  • Research Organizations
  • Animal
  • Human
  • Microbial
    • Bacterial
    • Viral
  • Synthetic
  • Continuous Manufacturing
  • Downstream Processing
  • Upstream Processing
  • Intravenous
  • Subcutaneous
  • Large Molecule
  • Small Molecule
  • Clinical
  • Preclinical
  • Endocrinology
  • Immunology
    • Allergies
    • Immunodeficiency
  • Direct Sales
  • Distributor Sales
  • Online Sales
  • Off-Patent
  • Patented
  • Over-The-Counter
  • Prescription-Based
  • Acute
  • Chronic

This research report categorizes the Biologics & Biosimilars CXO Services Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biologics & Biosimilars CXO Services Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Alexion Pharmaceuticals, Inc. (Acquired by AstraZeneca)
  • Amgen Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Fresenius Kabi
  • Genentech, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V. (Acquired by Viatris Inc.)
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi S.A.
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics & Biosimilars CXO Services Market, by Product Type
8.1. Introduction
8.2. Cell Therapy
8.3. Gene Therapy
8.4. Hormones
8.5. Monoclonal Antibodies
8.6. Recombinant Proteins
8.7. Vaccines
9. Biologics & Biosimilars CXO Services Market, by Application
9.1. Introduction
9.2. Autoimmune Diseases
9.2.1. Crohn's Disease
9.2.2. Rheumatoid Arthritis
9.3. Cardiovascular Diseases
9.4. Infectious Diseases
9.5. Neurological Disorders
9.6. Oncology
9.6.1. Breast Cancer
9.6.2. Colorectal Cancer
9.6.3. Lung Cancer
10. Biologics & Biosimilars CXO Services Market, by End-User
10.1. Introduction
10.2. Clinics
10.3. Contract Manufacturing Organizations
10.4. Hospitals
10.5. Research Organizations
11. Biologics & Biosimilars CXO Services Market, by Source
11.1. Introduction
11.2. Animal
11.3. Human
11.4. Microbial
11.4.1. Bacterial
11.4.2. Viral
11.5. Synthetic
12. Biologics & Biosimilars CXO Services Market, by Manufacturing Process
12.1. Introduction
12.2. Continuous Manufacturing
12.3. Downstream Processing
12.4. Upstream Processing
13. Biologics & Biosimilars CXO Services Market, by Route Of Administration
13.1. Introduction
13.2. Intravenous
13.3. Subcutaneous
14. Biologics & Biosimilars CXO Services Market, by Molecular Type
14.1. Introduction
14.2. Large Molecule
14.3. Small Molecule
15. Biologics & Biosimilars CXO Services Market, by Development Stage
15.1. Introduction
15.2. Clinical
15.3. Preclinical
16. Biologics & Biosimilars CXO Services Market, by Therapeutics Area
16.1. Introduction
16.2. Endocrinology
16.3. Immunology
16.3.1. Allergies
16.3.2. Immunodeficiency
17. Biologics & Biosimilars CXO Services Market, by Sales Channel
17.1. Introduction
17.2. Direct Sales
17.3. Distributor Sales
17.4. Online Sales
18. Biologics & Biosimilars CXO Services Market, by Patent Status
18.1. Introduction
18.2. Off-Patent
18.3. Patented
19. Biologics & Biosimilars CXO Services Market, by Drug Classification
19.1. Introduction
19.2. Over-The-Counter
19.3. Prescription-Based
20. Biologics & Biosimilars CXO Services Market, by Treatment Duration
20.1. Introduction
20.2. Acute
20.3. Chronic
21. Americas Biologics & Biosimilars CXO Services Market
21.1. Introduction
21.2. Argentina
21.3. Brazil
21.4. Canada
21.5. Mexico
21.6. United States
22. Asia-Pacific Biologics & Biosimilars CXO Services Market
22.1. Introduction
22.2. Australia
22.3. China
22.4. India
22.5. Indonesia
22.6. Japan
22.7. Malaysia
22.8. Philippines
22.9. Singapore
22.10. South Korea
22.11. Taiwan
22.12. Thailand
22.13. Vietnam
23. Europe, Middle East & Africa Biologics & Biosimilars CXO Services Market
23.1. Introduction
23.2. Denmark
23.3. Egypt
23.4. Finland
23.5. France
23.6. Germany
23.7. Israel
23.8. Italy
23.9. Netherlands
23.10. Nigeria
23.11. Norway
23.12. Poland
23.13. Qatar
23.14. Russia
23.15. Saudi Arabia
23.16. South Africa
23.17. Spain
23.18. Sweden
23.19. Switzerland
23.20. Turkey
23.21. United Arab Emirates
23.22. United Kingdom
24. Competitive Landscape
24.1. Market Share Analysis, 2024
24.2. FPNV Positioning Matrix, 2024
24.3. Competitive Analysis
24.3.1. Alexion Pharmaceuticals, Inc. (Acquired by AstraZeneca)
24.3.2. Amgen Inc.
24.3.3. Biocon Limited
24.3.4. Boehringer Ingelheim GmbH
24.3.5. Celltrion, Inc.
24.3.6. Dr. Reddy's Laboratories Limited
24.3.7. Eli Lilly and Company
24.3.8. Fresenius Kabi
24.3.9. Genentech, Inc.
24.3.10. Lupin Limited
24.3.11. Merck & Co., Inc.
24.3.12. Mylan N.V. (Acquired by Viatris Inc.)
24.3.13. Pfizer Inc.
24.3.14. Samsung Bioepis Co., Ltd.
24.3.15. Sandoz International GmbH
24.3.16. Sanofi S.A.
24.3.17. STADA Arzneimittel AG
24.3.18. Teva Pharmaceutical Industries Ltd.
25. ResearchAI
26. ResearchStatistics
27. ResearchContacts
28. ResearchArticles
29. Appendix
List of Figures
FIGURE 1. BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 26. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2024 VS 2030 (%)
FIGURE 28. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2024 VS 2030 (%)
FIGURE 30. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
FIGURE 32. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 36. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 38. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 39. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 40. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 41. BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 42. BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ANIMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ALLERGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY OFF-PATENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY CHRONIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 123. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 126. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 127. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 129. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 130. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 131. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 133. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 134. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 135. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 138. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 139. CANADA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 210. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 213. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 214. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 216. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 217. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 218. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 220. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 221. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 222. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 225. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 226. CHINA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 227. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 230. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 231. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 233. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 234. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 235. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 237. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 238. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 239. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 242. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 243. INDIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 269. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 271. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 272. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 274. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PATENT STATUS, 2018-2030 (USD MILLION)
TABLE 276. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 277. JAPAN BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY MOLECULAR TYPE, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA BIOLOGICS & BIOSIMILARS CXO SERVICES MARKET SIZE, BY THERAPEUTICS AREA, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA BIOLOGICS & BIOS

Companies Mentioned

  • Alexion Pharmaceuticals, Inc. (Acquired by AstraZeneca)
  • Amgen Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Fresenius Kabi
  • Genentech, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V. (Acquired by Viatris Inc.)
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi S.A.
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biosimilars of Factor X agonists Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Biosimilars of Factor X agonists Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global, United States Global, United States
From
Biopharmaceuticals Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Biopharmaceuticals Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global, United States Global, United States
From
Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players - Product Image

Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players

  • Report
  • 319 Pages
  • Global
From
Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Biosimilar Testing and Development Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Biosimilar Testing and Development Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.